

# Precision Medicine Initiative (PMI) Committee Meeting

September 20, 2023

# Agenda









- Role Call
- Project Status Updates
- Project Discussion Items
- Next Steps

# Stakeholder Representation

<input checked="" type="checkbox"/>	Alliance	<input checked="" type="checkbox"/>	ECOG-ACRIN	<input checked="" type="checkbox"/>	CCTG
<input checked="" type="checkbox"/>	NRG	<input type="checkbox"/>	COG	<input checked="" type="checkbox"/>	SWOG
<input type="checkbox"/>	Nationwide	<input type="checkbox"/>	MD Anderson	<input type="checkbox"/>	MOCHA

# Project Status Updates

# Project Updates – PMI Deliverables

	Deliverable	Target Release Date	Target Release Vehicle
	<b>ComboMATCH changes</b> (Disease fields, histology, behavior field code)	<b>PROD Released:</b> July 17, 2023	Screening Protocol EC Template v2.0
	<b>Designated Labs for Combo</b>	<b>PROD Released:</b> Sept 6, 2023	<b>Screening Protocol EC Template v3.0</b> (UAT Release w/EA – 07/27/2023)
	<b>Re-Screening ComboMATCH</b>	<i>PROD Release: Sept 27, 2023</i>	<b>MSRP Re-Screening EC Template v1.0</b> (UAT Release w/EA – 07/27/2023)
	<b>Cohort Migration</b>	<i>PROD OPEN Release: Sept 28, 2023</i>	<b>Treatment Protocol Cohort Migration EC Template v1.0</b> (UAT Release w/TX Groups – 09/15/2023; PROD EC Template v1.0 date TBD)
		<i>PROD EC Temp v1.0: Oct tbd, 2023</i>	
	<b>MyeloMATCH Tx Protocol Crossover</b> (for S01, CTG01 and EA02)	<i>PROD OPEN Release: October 3, 2023</i>	Part of the existing Treatment Protocol workflow.
	<b>Re-Screening MM</b>	<i>PROD OPEN Release: Oct 9, 2023</i>	<b>MSRP Re-Screening EC Template v2.0</b> (UAT Release w/SWOG – 09/25/2023; PROD RS EC Template v2.0 date TBD)
		<i>PROD RS EC Temp v2.0: Oct tbd, 2023</i>	
	<b>MyeloMATCH Stratification</b>	<i>PROD OPEN Release: Nov 15, 2023</i>	Part of existing Treatment Protocol Workflow.
	<b>BETA PMI Screening Protocol ALS v2.0</b> <i>New Forms: STMF, CLIA, PATH GROUP</i>	<i>BETA Release: Dec 22, 2023</i>	Target date for BETA Release for Groups to initiate UAT activities. (accompanied by BETA Screening Protocol Central Study ALS v2.0)
	<b>PROD PMI Screening Protocol ALS v2.0</b> <i>New Forms: STMF, CLIA, PATH GROUP</i>	<i>PROD Release: Feb 26, 2023</i>	Target date for PRODUCTION Release for Groups to initiate implementation activities. (accompanied by PROD Screening Protocol Central Study ALS v2.0)

# Project Updates - EC Template Release Schedule

	Template	Version	Release Date	Details
	PMI Screening Protocol EC Template	V1.0	<b>PROD Released:</b> Feb 15, 2023	
	PMI Screening Protocol EC Template	V2.0	<b>PROD Released:</b> July 17, 2023	Includes CM changes (Disease fields, histology, behavior field code)
	PMI Screening Protocol EC Template	V3.0	<b>PROD Released:</b> Sept 6, 2023	Includes updates for Designated Labs (DLAP fields)
	PMI Screening Protocol EC Template	V4.0	<i>*Cancelled</i>	<i>MM-MSRP changes (Provisional Diagnosis Question)</i> *A non-EC form approach adopted; provisional diagnosis will not be captured on the MSRP Screening EC; final diagnosis will be provided as part of the patient's treatment assignment.
	PMI Treatment Protocol EC Template	V1.0	<b>PROD Released:</b> Feb 15, 2023	
	PMI MSRP Re-Screening EC Template	V1.0	<i>PROD Release: Sept 27, 2023</i>	<i>Supports ComboMATCH MSRP</i>
	PMI MSRP Re-Screening EC Template	V2.0	<i>PROD Release: Oct tbd, 2023</i>	<i>Supports MyeloMATCH MSRP</i>
	PMI Treatment Protocol Cohort Migration EC Template	V1.0	<i>PROD Release: Oct tbd, 2023</i>	<i>Supports cohort migration activities for both ComboMATCH</i>

# Project Updates - EC Template Release Schedule

... slide edited post meeting.

	Template	Version	UAT Release Date	PROD Release Date	Details
✓	PMI Screening Protocol EC Template	V1.0	Released: 12/16/2023	Released: 02/15/2023	
✓	PMI Screening Protocol EC Template	V2.0	Released: 05/01/2023	Released: 07/17/2023	Includes CM changes (Disease fields, histology, behavior field code)
✓	PMI Screening Protocol EC Template	V3.0	Released: 07/27/2023	Released: 09/06/2023	Includes updates for Designated Labs (DLAP fields)
✗	PMI Screening Protocol EC Template	V4.0		*Cancelled	<del>MM-MSRP changes (Provisional Diagnosis Question)</del> *A non-EC form approach adopted; provisional diagnosis will not be captured on the MSRP Screening EC; final diagnosis will be provided as part of the patient's treatment assignment.
✓	PMI Treatment Protocol EC Template	V1.0	Released: 12/16/2023	Released: 02/15/2023	
□	PMI MSRP Re-Screening EC Template	V1.0	Released: 07/27/2023	Target: 09/27/2023	Supports ComboMATCH MSRP.
□	PMI MSRP Re-Screening EC Template	V2.0	Target: 09/25/2023	Target: 10/xx/2023	Supports MyeloMATCH MSRP; PROD release date to be determined.
□	PMI Treatment Protocol Cohort Migration EC Template	V1.0	Released: 09/18/2023	Target: 10/xx/2023	Supports cohort migration activities for ComboMATCH; PROD release date to be determined.

# ComboMATCH Priority 1 List

#	Protocol #	Protocol Title	Group	Activated	Current Status
1	EAY191	Molecular Analysis for Combination Therapy Choice (ComboMATCH)	ECOG-ACRIN	Yes	9/20: CTEP requested an amendment for EAY191 to remove SSN and Hospital Number. We anticipate activating this and another amendment on 9/27. Plan to combine these updates to OPEN with the addition of "Reassignment/Step 2" functionality on 9/27/2023.
2	EAY191-N4	Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers A ComboMATCH Treatment Trial	NRG	Yes	9/20: Working with CTSU on incorporating ineligibility requirements
3	EAY191-E4	A ComboMATCH Treatment Trial ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors	ECOG-ACRIN	Yes	9/20: Need to incorporate ineligibility
4	EAY191-N2	A ComboMATCH Treatment Trial EAY191-N2: Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1	NRG	Yes	9/20: Need to incorporate ineligibility and cohort migration
5	EAY191-S3	Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors	SWOG	Yes	9/20: Need to incorporate ineligibility <b>**Project team to send over additional information for implementation</b>



## ComboMATCH Priority 2 List

#	Protocol #	Protocol Title	Group	Activated	Current Status
6	EAY191-A6	A ComboMATCH Treatment Trial: FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations	Alliance	Yes	9/20: Need to incorporate ineligibility
7	EAY191-A3	Palbociclib and Binimetinib in RAS-Mutant Cancers	Alliance	No	9/20: Need to incorporate ineligibility and cohort migration

## ComboMATCH Priority 3 List

#	Protocol #	Protocol Title	Group	Current Status
8	EAY191-A2	Olaparib Plus Low-Dose Alpelisib for Breast Cancer	Alliance	<b>9/20:</b> Dropped
9	EAY191-C1	Phase 2 Subprotocol of the Combination of a MEK Inhibitor and a Pan-RAF Inhibitor in Patients with Relapsed/Refractory Tumors Harboring Activating MAPK Pathway Mutations	COG	<b>9/20:</b> No attendance at meeting
10	EAY191-E5	ComboMATCH Treatment Trial E5: A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors	ECOG-ACRIN	<b>9/20:</b> Working on new Cohort Migration EC template; having interactive review for study build today
11	EAY191-N5	Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N5: A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors A ComboMATCH Treatment Trial	NRG	<b>9/20:</b> Protocol was submitted on 9/15 to PIO; starting study build but hoping for an extension; date is Oct 23 <sup>rd</sup> – No cohort migration, just a crossover David will follow up with NRG and the Pis; cannot verify copy number loss; my require a protocol update  David will send Rich the language to send to the sites to update

# MyeloMATCH Priority 1 List

#	Protocol #	Protocol Title	Group	Current Status
1	MYELOMATCH	Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials	SWOG	<p><b>9/20:</b> Need to know which version of the ALS should be used; which version of the EC template and which features do you expect to activate with?</p> <p>SWOG should proceed with Screening Protocol ALS v1.0 and PMI Screening Protocol EC Template v3.0</p> <p>Step 2 Rescreening will not be required for the initial build No Specimen forms needed for initial activation</p>
2	MM1YA-S01	A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) to (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and Azacitidine + Venetoclax in Patients Aged 59 or Younger with High-Risk (Adverse) Acute Myeloid Leukemia; A MYELOMATCH Clinical Trial	SWOG	<p><b>9/20:</b> Will provide an update next meeting; is using an old EC template.</p>
3	MM1YA-CTG01	A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial	CCTG	<p><b>9/20:</b> No updates</p>
6	MM10A-EA02 (Concept)	A Randomized Phase II Study of HMA-Based Therapies for the Treatment of Older Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia: A myeloMATCH Treatment Trial	ECOG-ACRIN	<p><b>9/20:</b> Started looking at study build, no OPEN work started yet</p>

## MyeloMATCH Priority 2 List

#	Protocol #	Protocol Title	Group	Current Status
4	MM2YA-EA01	Eradicating Measurable Residual Disease in Patients with Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial	ECOG-ACRIN	9/20 – No Updates
5	MM10A-S02	A Randomized Phase II Study of Targeted Agents with the Oral DNMT1 Inhibitor Cedazuridine-Decitabine (ASTX727) for the Treatment of Newly Diagnosed TP53-Mutated Acute Myeloid Leukemia in Older Patients: A myeloMATCH Treatment Trial	SWOG	9/20 – Will work on this after S01 is tested and completed to copy functionality
7	MM1MDS-EA03 (Concept)	ERADICATE MDS with TP53 Study: Efficacy of targeted Agents Combinations with Oral DNMT1 Inhibitor C-DEC (ASTX727) for Treatment of Higher Risk myelodysplastic Syndromes with TP53 Mutations: A Non-Comparative, Parallel, Multi-Arm Phase 2 Study	ECOG-ACRIN	9/20 – No Updates

# PMI Project Discussion Items

# Open Discussion

- Cohort Migration – Help Text
  - Ginger will send out updated text per the call for final confirmation

# Next Steps

# Next Steps

Next meeting will be on 10/4/2023 at 1:00pm EST

## Agenda

- Role Call
- Project Status Update
- Group Status Update
- Review FAQs



# Communication



**Contact the PMI Mailbox for any PMI related questions & comments**

[pmistandards@nih.gov](mailto:pmistandards@nih.gov)

The project team will respond within 48 hours with a response or a follow up



**PMI Wiki**

<https://wiki.nci.nih.gov/display/CDISC/Precision+Medicine+Initiative>

All presentations, recordings, minutes, project documents and releases will be posted on this wiki




**NATIONAL  
CANCER  
INSTITUTE**

[www.cancer.gov](http://www.cancer.gov)


[www.cancer.gov/espanol](http://www.cancer.gov/espanol)

# Appendix

# Target Timeline



# Target Timeline



## ComboMATCH Priority 1 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps	Primary Agent Name (P) Other Agent Name (O)
1	EAY191	Molecular Analysis for Combination Therapy Choice (ComboMATCH)	ECOG-ACRIN	8/15/2022 Approval on Hold	Revision 3 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	
2	EAY191-N4	Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers A ComboMATCH Treatment Trial	NRG	8/15/2022 Approval on Hold	Revision 4 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	(P) Olaparib (AZD2281) (747856) (O) Selumetinib (AZD6244 hydrogen sulfate) (748727)
3	EAY191-E4	A ComboMATCH Treatment Trial ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors	ECOG-ACRIN	8/26/2022 Approval on Hold	Revision 3 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	(P) Nilotinib (747599) (O) Paclitaxel (Taxol) (673089)
4	EAY191-N2	A ComboMATCH Treatment Trial EAY191-N2: Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1	NRG	8/26/2022 Approval on Hold	Revision 3 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	(P) Binimetinib (788187) (O) Fulvestrant (Faslodex) (719276)
5	EAY191-S3	Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors	SWOG	8/29/2022 Approval on Hold	Revision 4 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	(P) Ipatasertib (781451) (O) Paclitaxel (Taxol) (673089)

## ComboMATCH Priority 2 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps	Primary Agent Name (P) Other Agent Name (O)
6	EAY191-A6	A ComboMATCH Treatment Trial: FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations	Alliance	Approval on Hold 9/14/2022	Rev 4 approved by CIRB on 10/24. CTEP currently reviewing stips.	(P) Binimetinib (788187) (O) OXALIplatin (Eloxatin) (266046) (O) 5-Fluorouracil (5-FU) (19893) (O)Leucovorin calcium (3590)
7	EAY191-A3	Palbociclib and Binimetinib in RAS-Mutant Cancers	Alliance	Approval on Hold 8/26/2022	Rev 2 sent to CIRB . Reviewed on 10/6, study team responding to stips	(P) Palbociclib (PD-0332991) (772256) (O) Binimetinib (788187)

## ComboMATCH Priority 3 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps	Primary Agent Name (P) Other Agent Name (O)
8	EAY191-A2	Olaparib Plus Low-Dose Alpelisib for Breast Cancer	Alliance	In Review 4/4/2022	Rev 3 recv;d 10/19, currently with LR. Looks like it'll be another disapproval. Not yet sent to CIRB for initial review.	(P) Olaparib (AZD2281) (747856) (O) Alpelisib (BYL719) (801658)
9	EAY191-C1	Phase 2 Subprotocol of the Combination of a MEK Inhibitor and a Pan-RAF Inhibitor in Patients with Relapsed/Refractory Tumors Harboring Activating MAPK Pathway Mutations	COG	In Review 9/29/2022	Protocol reviewed at PRC 10/20; CR is being put together	(P) Selumetinib (AZD6244 hydrogen sulfate) (748727) (O) DAY101 (TAK-580, MLN-2480) (800798)
10	EAY191-E5	ComboMATCH Treatment Trial E5: A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors	ECOG-ACRIN	In Review 2/22/2022	Waiting for revision 2 since 9/28; reminder was sent to EA 10/24	(P) AMG 510 (Sotorasib) (825510) (O) Panitumumab (742319)
11	EAY191-N5	Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N5: A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors A ComboMATCH Treatment Trial	NRG	In Review 11/22/2021	Rev 3 disapproval sent 10/15; waiting for Rev 4	(P) Neratinib (783782) (O) Palbociclib (PD-0332991) (772256)



## MyeloMATCH Priority 1 List


Study #	Document Number	Document Title	Group	Current Status	Next Steps
1	MYELOMATCH	Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials	SWOG	11/12/2021: Approval on Hold	CIRB Reviewed on 9/15, version with stips under CTEP review now.
2	MM1YA-S01	A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) to (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and Azacitidine + Venetoclax in Patients Aged 59 or Younger with High-Risk (Adverse) Acute Myeloid Leukemia; A MYELOMATCH Clinical Trial	SWOG	9/2/2022: Approval on Hold	CIRB Reviewed on 9/15, version with stips under CTEP review now.
3	MM1YA-CTG01	A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial	CCTG	9/2/2022: Approval on Hold	CIRB Review Oct 6, responding to stips
6	MM10A-EA02 (Concept)	A Randomized Phase II Study of HMA-Based Therapies for the Treatment of Older Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia: A myeloMATCH Treatment Trial	ECOG-ACRIN	8/29/2022: Approved, no protocol yet	Waiting for protocol

## MyeloMATCH Priority 2 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps
4	MM2YA-EA01	Eradicating Measurable Residual Disease in Patients with Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial	ECOG-ACRIN	1/21/2022: In Review	Reviewed by CIRB, responding to stips
5	MM10A-S02	A Randomized Phase II Study of Targeted Agents with the Oral DNMT1 Inhibitor Cedazuridine-Decitabine (ASTX727) for the Treatment of Newly Diagnosed TP53-Mutated Acute Myeloid Leukemia in Older Patients: A myeloMATCH Treatment Trial	SWOG	10/17/2022: In Review	Scheduled for PRC 11/4
7	MM1MDS-EA03 (Concept)	ERADICATE MDS with TP53 Study: Efficacy of targeted Agents Combinations with Oral DNMT1 Inhibitor C-DEC (ASTX727) for Treatment of Higher Risk myelodysplastic Syndromes with TP53 Mutations: A Non-Comparative, Parallel, Multi-Arm Phase 2 Study	ECOG-ACRIN	8/12/2022: Approval on hold, waiting for drug commitment	W+A6:G8aiting for Astex commitment, Genentech has provided commitment on 10/20

# Review Schemas


# EAY191-N4




# EAY191-E4



# EAY191-N2- Draft



# EAY191-S3



# MMIYA-CTG01 Draft

